Wafaa El-Sadr, MD, MPH, MPA, global director of ICAP, was quoted by Al Jazeera, on Dec. 19 for her review of the similarities and differences of the two COVID-19 vaccines approved by the FDA. Dr. El-Sadr points out the Moderna Inc. and Pfizer-BioNTech vaccines are both about 94 to 95 percent effective and are similar in several ways:
“They’re similar in that they both use the same technology, the same approach to making he vaccine. They both require two doses. These two vaccines work incredibly well.”
Read the full article in Al Jazeera
Read the latest ICAP updates on COVID-19 here
A major global health organization that has been improving public health in countries around the world for over 15 years, ICAP works to transform the health of populations through innovation, science, and global collaboration. Based at Columbia University in New York City, where it is part of the Mailman School of Public Health, ICAP has projects in more than 30 countries, working side-by-side with ministries of health and local partners to confront some of the world’s toughest health challenges. Through meaningful research, tailored technical assistance, effective training and education programs, and rigorous surveillance to measure and evaluate the impact of public health interventions, ICAP aims to realize a global vision of healthy people, empowered communities, and thriving societies. Online at icap.columbia.edu
